Leading Pharma Companies Help Shape New Accenture Life Sciences Cloud for R&D
Eisai Co., Ltd., Merck & Co., Inc. and Pfizer Inc. join with Accenture to build a standards-driven platform powered by Oracle to help simplify and speed drug development
NEW YORK, Oct 09, 2014 (BUSINESS WIRE) -- Accenture ACN, -1.73% has announced the launch of Accenture Life Sciences Cloud for R&D which speeds clinical development, helps improve patient outcomes and creates greater R&D efficiency through a new single analytics platform that brings together multiple internal and external data sources across clinical, safety, regulatory and operational functions.
In parallel with the Accenture Life Sciences Cloud for R&D platform, Accenture has formed a Life Sciences Cloud Coalition, which includes Eisai, Merck and Pfizer. The aim of this group is to collaborate on bringing innovation to the Accenture Life Sciences Cloud and digitally enable the R&D function, speed up the drug development process while improving quality and cost for the industry.
The Accenture Life Sciences Cloud for R&D is part of Accenture Accelerated R&D Services, a business service focused on building more efficient and effective R&D models, partnering with the industry from early clinical trials to regulatory approvals and throughout the product lifecycle.
"With the cost of healthcare – particularly for drug development – escalating faster than the gross domestic product of nearly every economy around the world, pharmaceutical companies are facing huge pressure to seek efficiencies in R&D," said Kevin Julian, managing director of Accenture Accelerated R&D Services. "New technologies, analytic capabilities and a willingness by drug manufacturers to collaborate can help mitigate rising costs. These can be leveraged to provide a much clearer view of the clinical results by collecting and analyzing data and information in real time—beginning with the development cycle."
The foundation of the Accenture Life Sciences Cloud for R&D is an alliance between Accenture and Oracle. The solutions developed by the alliance are built on a combination of Oracle's deep expertise and experience in developing and hosting mission-critical Clinical Data Warehousing and analytics applications for life sciences, coupled with Accenture's proven implementation experience to deliver best-in-class service-based solutions. The Accenture Life Sciences Cloud for R&D utilizes Oracle datacenters around the globe to host clinical applications such as Oracle Life Sciences Data Hub and Oracle Clinical Development Analytics.
Key features of the Accenture Life Sciences Cloud for R&D include a:
- Clinical Trial and Scientific Data Warehouse for storing, managing, searching and reporting on patient data to improve strategic decision making, including spotting promising drugs earlier and decreasing investment in drugs that may not succeed.
- Operational Data Warehouse for gathering vital metrics to monitor clinical trial portfolios, manage vendor relationships and address any operational issues.
- Information eXchange Hub to provide an integration and security layer to manage users, data sources, on-premise systems and other cloud providers to support a virtual, seamless aggregation of data.
- Scalable, secure, regulatory-compliant cloud platform utilizing Oracle Engineered Systems hosted in Oracle datacenters. The platform is available as a private cloud and designed for both large- and small-scale implementations with the ability to handle high data volumes and service level requirements.
"With the Accenture Life Sciences Cloud for R&D, clinical R&D organizations can benefit from a proven, mature, infrastructure platform purposefully built and implemented with industry best practices to deliver accelerated ROI, with reduced risk and time to value," said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. "Oracle provides the software and infrastructural foundation for this initiative that promises to redefine how organizations manage clinical data both today and tomorrow, given the rapid advances in technology and clinical science.
"R&D leaders from Eisai, Merck and Pfizer are participating in the Accenture Life Sciences Cloud Coalition to determine the future development roadmap and evolution of the platform, ensuring that the solution is being built by the industry for the industry," said Julian. "With some of the largest pharmaceutical companies in the world coming together in the interest of conducting clinical trials in a much more efficient and cost-effective way that will benefit the patients they serve, this has been an amazingly collaborative effort."
Accenture is a global management consulting, technology services and outsourcing company, with more than 305,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world's most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$30.0 billion for the fiscal year ended Aug. 31, 2014. Its home page is www.accenture.com.
Oracle and Java are registered trademarks of Oracle and/or its affiliates.